KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)Dividends Paid - Common (QoQ)Dividends Paid - Common Growth (1y)Dividends Paid - Common Growth (3y)Dividends Paid - Common Growth (5y)Dividends payables Growth (1y)Dividends payables Growth (3y)Dividends payables Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)FCF Payout Ratio (QoQ)FCF Payout Ratio Growth (1y)FCF Payout Ratio Growth (3y)FCF Payout Ratio Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Invested Capital Growth (1y)Return on Invested Capital Growth (3y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Share-based Compensation Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Tax Rate (QoQ)Tax Rate Growth (1y)Tax Rate Growth (3y)Tax Rate Growth (5y)Total Debt (QoQ)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)
Income Statement
Others
Ratios

Pfizer (PFE) Cash & Equivalents Growth (1y) (2010 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 70.76%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -43.63%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 81.47%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -38.27%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 36.64%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -3.76%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 19.09%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -11.96%
10 Gsk 88.34 Bn 83.66 Bn - -9.03%

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 19.09%
Dec 31, 2025 9.49%
Sep 28, 2025 22.99%
Jun 29, 2025 55.70%
Mar 30, 2025 98.89%
Dec 31, 2024 -63.44%
Sep 29, 2024 -65.31%
Jun 30, 2024 -60.03%
Mar 31, 2024 -66.81%
Dec 31, 2023 585.82%
Oct 1, 2023 142.53%
Jul 2, 2023 47.87%
Apr 2, 2023 -12.31%
Dec 31, 2022 -78.60%
Oct 2, 2022 -33.98%
Jul 3, 2022 -24.96%
Apr 3, 2022 39.71%
Dec 31, 2021 8.85%
Oct 3, 2021 23.88%
Jul 4, 2021 31.70%
Apr 4, 2021 -17.81%
Dec 31, 2020 59.32%
Sep 27, 2020 -43.02%
Jun 28, 2020 0.95%
Mar 29, 2020 11.05%
Dec 31, 2019 -1.58%
Sep 29, 2019 -21.75%
Jun 30, 2019 -34.02%
Mar 31, 2019 -19.83%
Dec 31, 2018 -20.41%
Sep 30, 2018 24.53%
Jul 1, 2018 1.62%
Apr 1, 2018 -41.52%
Dec 31, 2017 -46.32%
Oct 1, 2017 36.49%
Jul 2, 2017 -21.99%
Apr 2, 2017 61.30%
Dec 31, 2016 -28.08%
Oct 2, 2016 -32.43%
Jul 3, 2016 -7.06%
Apr 3, 2016 -28.12%
Dec 31, 2015 10.89%
Sep 27, 2015 27.16%
Jun 28, 2015 7.75%
Mar 29, 2015 24.49%
Dec 31, 2014 53.14%
Sep 28, 2014 18.76%
Jun 29, 2014 39.82%
Mar 30, 2014 51.27%
Dec 31, 2013 -78.35%
Sep 29, 2013 -54.46%
Jun 30, 2013 -19.63%
Mar 31, 2013 -35.51%
Dec 31, 2012 216.81%
Sep 30, 2012 21.59%
Jul 1, 2012 -2.10%
Apr 1, 2012 301.92%
Dec 31, 2011 83.40%
Oct 2, 2011 70.31%
Jul 3, 2011 64.94%
Apr 3, 2011 -58.50%
Dec 31, 2010 -12.29%
Oct 3, 2010 -48.61%
Jul 4, 2010 -16.35%
Apr 4, 2010 41.06%